SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The $CAW (crow with knife) crypto meme coin is buzzing, with the community highlighting its multichain presence and deflationary mechanisms. Discussions mention potential staking opportunities and tout the strength of the community, frequently using the term "WAGMI" (we are all going to make it). The coin's association with other meme projects like $SLAP, $RAGE and $BROKE is also part of the conversation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending amidst election results and discussions around its financial performance. The community is debating the stock's valuation, potential for a 'sandbag' event, and the impact of political events on its future. Some users are expressing concerns about the company's business model and leadership, while others remain supportive.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid broad market concerns about AI valuations and a potential correction, despite recent positive earnings from some tech companies. Community sentiment is mixed, with some traders anticipating a bounce while others brace for further declines, potentially exacerbated by the ongoing government shutdown and election outcomes. News of global selloffs and concerns from major financial figures are adding to the market's uncertainty.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is experiencing high volatility, fueled by discussions around a potential Trump partnership and recent market dips. The community is split between those seeing current prices as a buying opportunity and those expressing frustration with the coin's performance and leadership. Some investors are closely watching for news related to Trump Media and crypto.com/us's bank charter application, anticipating these developments may influence $CRO's trajectory.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz ($HTZ) is trending amid discussions of a potential short squeeze, driven by positive earnings reports and high short interest. The community is actively debating whether it could become the next meme stock with potential for a significant run. Investors are also following Bill Ackman's involvement and awaiting analyst upgrades.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors digest recent earnings and future outlook, with discussion focused on whether the results justify the stock's valuation. Community talking points include the impact of AI infrastructure demand, potential competition with NVDA, and the influence of analyst price targets. Some are concerned about high expectations already being priced in, while others remain bullish on AMD's long-term prospects in the AI and data center markets.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

APPS is trending due to strong Q2 earnings, including revenue and adjusted EBITDA beats, and raised FY26 revenue guidance, sparking optimism about the company's turnaround. Community members are discussing potential catalysts like Google's app store changes and AI opportunities, with some setting price targets based on these developments. Short squeeze potential and debt refinancing are also hot topics, adding to the bullish sentiment.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing increased volatility as traders digest recent election results and their potential impact on economic policy. The community is expressing strong opinions on the market's direction and the implications of political outcomes. Discussions range from potential government shutdowns to the influence of specific political figures on market performance.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is trending as the community discusses its recent price surge and potential catalysts. The token's strong performance is attributed to increased activity on the BNB Chain and speculation around new partnerships. Community members are also closely watching for potential pullbacks and future upside targets.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors digest recent earnings and forward guidance, with debates focusing on revenue forecasts versus concerns about shrinking margins. Community discussions revolve around whether the company's management can execute its long-term vision, especially amid increased competition in the AI server market. Some traders see the dip as a buying opportunity, while others express skepticism about the company's ability to improve profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx initiative, which could increase Medicare coverage and unlock new reimbursement opportunities.</li><li>Retail sentiment on Stocktwits was ‘extremely bullish’ for both companies, with investors predicting LLY could hit over $920 and NVO rebounding after TrumpRx deals.</li><li>The TrumpRx deals are set to be the third major pricing pact since September, following similar agreements with Pfizer and AstraZeneca to lower U.S. drug prices in exchange for tariff relief.</li></ul>Retail chatter about Eli Lilly and Novo Nordisk surged on Tuesday after reports that both companies are preparing to announce deals with the Trump administration to cut U.S. prices of their weight-loss drugs in exchange for Medicare coverage, the federal insurance program for older Americans.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> extended its winning streak to four sessions on Tuesday, rising 1.2%, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> saw its losing streak stretch to 11 sessions, dropping 1.8%.<h2 class="st-heading-2">Lilly And Novo Near Agreements To Offer Discounted Drugs&nbsp;</h2>A White House source told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-novo-nordisk-near-white-house-deal-obesity-drug-prices-endpoints-new-2025-11-04/">Reuters</a> that the agreements could be unveiled Thursday morning at a White House event with pharmaceutical executives. The announcement would mark the third major pricing pact since September, following similar arrangements with Pfizer and AstraZeneca.According to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://endpoints.news/lilly-and-novo-near-white-house-deal-on-obesity-drugs-prices/">Endpoints News</a>, Lilly and Novo would offer the lowest dose of their weight-loss drugs for $149 per month, a move that could make their treatments far more accessible to Medicare beneficiaries while unlocking billions in new reimbursement opportunities. The Wall Street Journal separately&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/trump-negotiating-deal-with-ozempic-maker-to-sell-some-weight-loss-drugs-for-149-1eb49286">reported</a> that the administration is negotiating for lower-dose versions of the drugs to be sold through TrumpRx, a planned White House initiative for discounted medicines.<h2 class="st-heading-2">Zepbound And Wegovy Prices Expected to Drop</h2>The starting dose of Lilly’s Zepbound would reportedly&nbsp;cost $299, about $50 less than what patients currently pay on the company’s direct-to-consumer website. Novo Nordisk confirmed it was in “constructive discussions” with the Trump administration related to the president’s most-favored-nation executive order.White House spokeswoman Karoline Leavitt declined to confirm the deals but reiterated Trump’s commitment to reducing drug costs, saying, “We’re working with pharmaceutical companies to do that every day.”<h2 class="st-heading-2">Pfizer And AstraZeneca Tariff Relief Deals</h2>The reported Lilly and Novo negotiations&nbsp;follow Pfizer's September agreement to lower U.S. Medicaid prescription drug prices to match those in other developed nations in exchange for tariff relief. The deal was reached following Trump’s threat of a 100% tariff on branded and patented drugs, which broke a months-long stalemate in talks.A month later, AstraZeneca became the second company to reach a similar arrangement, pledging to cut prices across its portfolio for three years in exchange for relief from pharmaceutical tariffs. The British firm also agreed to sell discounted products through TrumpRx, expanding its direct-to-consumer offerings.Both Pfizer and AstraZeneca were pressured into the talks after Trump’s summer directive ordering 17 major drugmakers to voluntarily lower prices or face penalties.<h2 class="st-heading-2">Broader Push for ‘Most-Favored-Nation’ Pricing</h2>The Trump administration has pushed to link U.S. drug prices to those in other developed countries through a “most-favored-nation” policy, seeking to end what it describes as years of American patients subsidizing global pharmaceutical profits.On Stocktwits, retail sentiment for both Lilly and Novo was ‘extremely bullish’ amid ‘extremely high’ message volumes.<h2 class="st-heading-2">Stocktwits Users Bullish On LLY’s Four-Day Streak, NVO Faces Mixed Sentiment</h2>One user said that Eli Lilly was flashing "green" in their portfolio, highlighting its four-day winning streak. Another lauded the stock's performance, noting its "insane chart" and predicting further upside to $920 and $970.<stembedurl>https://stocktwits.com/Stonkapedia/message/634958970</stembedurl><stembedurl>https://stocktwits.com/Jgarcapital/message/634915642</stembedurl>In contrast, Novo Nordisk drew mixed reactions, with one user comparing it to Pfizer after&nbsp;COVID-19, suggesting the company may need to raise its dividend to reverse its losses.&nbsp;<stembedurl>https://stocktwits.com/Golferhack12/message/634947813</stembedurl>Another user noted Eli Lilly's market cap is four times that of Novo, but remained optimistic, predicting that upcoming earnings, potential TrumpRx initiatives, and pill approvals could push Novo's stock back to $62.<stembedurl>https://stocktwits.com/EmbraceVolatility/message/634936250</stembedurl>While Eli Lilly’s stock has risen 18% so far in 2025, Novo Nordisk’s U.S.-listed stock fell 43% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A board displays prescription drug price discounts to be available at TrumpRx.gov on October 10, 2025. (Photo by Andrew Harnik/Getty Images)

Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs

The TrumpRx deals are set to be the third major pricing pact since September, following similar agreements with Pfizer and AstraZeneca to lower U.S. drug prices in exchange for tariff relief.

Equity

Stock Bulls Get a Wake-Up Call from Wall Street CEOs  Open Interest 11/04/2025

Get a jump start on the US trading day with Matt Miller and Dani Burger on 'Bloomberg Open Interest.' Warning signs. Wall Street CEOs say investors should brace for a 10% correction in the next 12 to...

Pfizer and Novo Nordisk both raise bids for Metsera

CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera...

Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools

Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.

Metsera says Novo Nordisk's new bid for obesity drugmaker is 'superior' to revised Pfizer offer

The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in...

<ul class="summary-bullets"><li>Novo’s new proposal values Metsera at about $10 billion while Pfizer’s revised proposal values the company at about $8.1 billion.&nbsp;</li><li>Pfizer now has two business days to negotiate the terms of its agreement with Metsera.</li><li>As of date, Novo’s proposal constitutes a superior one to Pfizer’s, Metsera said.&nbsp; &nbsp;</li></ul>Metsera (MTSR) announced on Tuesday that it has received a revised acquisition proposal from Novo Nordisk (NVO) valuing the company at up to $86.20 per share or approximately $10 billion.The new proposal constitutes a superior proposal to its existing merger agreement with Pfizer, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/metsera-receives-amended-proposal-from-novo-nordisk-metsera-declares-novo-nordisk-amended-proposal-superior-302604143.html">noted</a>.<h2 class="st-heading-2">Revised Proposals</h2>Under the revised proposal, Novo Nordisk would pay Metsera $62.20 per Metsera common share in cash, up from $56.50 in the original proposal, immediately after the signing of a definite deal. Metsera would issue non-voting preferred stock to Novo Nordisk, representing 50% of Metsera's share capital in exchange.Following approval from shareholders and regulators, Metsera shareholders will then receive a contingent value right representing up to $24.00 per share in cash, an increase from $22.50 in the initial proposal, contingent upon the completion of certain milestones. Novo will then acquire the remainder of the outstanding shares.Metsera also said that Pfizer revised the terms of its agreement on Monday. Pfizer increased the upfront consideration to $60.00 per share in cash, up from $47.50, and decreased the amount payable under CVR to up to $10.00 per share in cash, down from $22.50, it said. The revised Pfizer proposal values Metsera at up to $70 per share or $8.1 billion.However, Novo’s proposal continues to be a superior one, and Pfizer has two business days to negotiate with Metsera for further adjustments to the terms and conditions of the merger agreement.Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior. However, at this time, the Pfizer Merger Agreement remains in full effect, it added.<h2 class="st-heading-2">Pfizer Hits Back At Novo Bid</h2>Novo Nordisk first announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Pfizer has since filed two lawsuits against the proposal.The lawsuit filed earlier this week against Metsera, its controlling stockholders and Novo Nordisk alleges that Novo Nordisk’s proposal to acquire Metsera constitutes an anticompetitive action by the company to protect its dominant market position in GLP-1 drugs by capturing and killing a nascent American competitor before it gains the support of Pfizer.Pfizer also filed a separate lawsuit last week against Metsera, its board and Novo, asserting claims for breach of contract and fiduciary duty. It has also filed a motion with the Court of Chancery, requesting that the court issue a temporary restraining order to block Metsera from terminating the merger agreement with itself.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>MTSR stock traded 20% higher at the time of writing. On Stocktwits, retail sentiment around Metsera stayed within the ‘extremely bullish’ territory while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> is up by 175% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-one-trillion-pay-package-gets-thumbs-up-from-baron-capital/cL28hdrR36i">Elon Musk’s $1T Pay Package Gets A Thumbs Up From Baron Capital</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters

Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal 'Superior' Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk...

<ul class="summary-bullets"><li>Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.</li><li>The report marks CEO Mike Doustdar’s first since taking charge, with investors watching for guidance on restructuring, job cuts, and strategy following a board overhaul.</li><li>The earnings release comes as Pfizer escalates its legal battle over Novo’s $9 billion bid for Metsera, accusing the company of trying to delay competition in the obesity drug market.</li></ul>Novo Nordisk will report its third-quarter (Q3) results on Wednesday, marking its first earnings release under new CEO Mike Doustdar. Analysts expect weaker profits and slower growth amid intensifying competition from Eli Lilly and mounting legal pressure from Pfizer.The company’s U.S.-listed stock fell 0.7% to close at $49.11 on Monday.<h2 class="st-heading-2">Analysts Expect Softer Quarter</h2>According to Koyfin estimates, analysts expect revenue of $11.87 billion, down 2% year-on-year. EBITDA is projected at $5.28 billion, a 13% decline, while EBIT is forecast to drop 26% to $3.92 billion. GAAP earnings per share (EPS) is seen at $0.70, compared with $0.94 a year earlier.BMO Capital Markets analyst Evan Seigerman said investors will be looking for signs of how Novo plans to get past restructuring and reignite obesity growth, after multiple guidance cuts this year, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ceo-faces-baptism-fire-amid-board-shakeup-pfizer-fight-2025-11-04/">report</a>.&nbsp;Jefferies analyst Michael Leuchten noted that Novo remains heavily dependent on semaglutide, the active ingredient in Wegovy and Ozempic, which underpins roughly 60% of future revenues. “It looks like the obesity market in the U.S. is running out of steam, and we don’t fully understand why,” Leuchten said, pointing to underwhelming new-patient starts.<h2 class="st-heading-2">Leadership Transition And Legal Uncertainty</h2>The report will also be the first under CEO Mike Doustdar, who took over in August after the Novo Nordisk Foundation, the company’s controlling shareholder, overhauled the board, replacing six independent directors. Former CEO Lars Rebien Sorensen is set to return as chairman following the Nov. 14 shareholder meeting.Paul Major, healthcare portfolio manager at Bellevue Asset Management, said the tone Doustdar sets on the company’s future strategy will be a point of focus, adding that investors are watching for alignment between management and the Foundation on Novo’s turnaround plan.<h2 class="st-heading-2">Pfizer Legal Dispute Adds Pressure</h2>The quarter also comes as Pfizer escalates its legal challenge over Novo’s $9 billion rival bid for Metsera, a U.S. biotech developing next-generation obesity drugs. Pfizer alleged that the Danish drugmaker structured the deal to delay competition and preserve market share for Wegovy and Ozempic.Novo has denied the claims, calling them “absurd” and arguing that it would accelerate Metsera’s commercialization if the claims were successful. The case will be heard on Tuesday.TD Cowen analyst Michael Nedelcovych said he will watch for any insights on the Metsera bid and whether Doustdar signals an appetite for further acquisitions.<h2 class="st-heading-2">Stocktwits Bulls View Novo’s Dip As A Buying Opportunity</h2>On Stocktwits, retail sentiment for both Novo Nordisk and Pfizer was ‘bullish’ amid ‘ high’ message volumes.One user commented that Novo Nordisk’s aggressive $6.5 billion bid for Metsera made it the biggest risk-taker in the dispute with Pfizer, adding that Metsera stood to benefit either way, while Pfizer faced litigation setbacks.<stembedurl>https://stocktwits.com/dyrtydave/message/634800076</stembedurl>Another said investors were overreacting to Novo’s share decline, describing it as a strong global company expanding its pipeline and calling the dip a potential buying opportunity.<stembedurl>https://stocktwits.com/Prit89/message/634764720</stembedurl><a href="https://stocktwits.com/Prit89/message/634764720">Novo Nordisk’s U.S.-listed stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.

Pfizer plays hardball in weight-loss drug fight

Pfizer has filed two lawsuits to block Novo Nordisk's $9bn bid to buy Metsera...

<ul class="summary-bullets"><li>Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.</li><li>Subscriber count grew 21% to almost 2.5 million, with monthly online revenue per subscriber up 19% to $80.</li><li>On Stocktwits, retail sentiment was ‘extremely bullish,’ with users predicting the stock could climb toward $50 once Novo Nordisk partnership talks conclude.</li></ul>Shares of Hims &amp; Hers Health rose about 5% in after-hours trading on Monday after the company reported another quarter of strong growth and said it’s in talks with Novo Nordisk to bring&nbsp;weight-loss drug Wegovy to its platform.<h2 class="st-heading-2">Revenue And Subscriber Growth Remain Strong</h2>Revenue rose 49% from a year earlier to $599 million as strength continued across the company’s weight-loss and wellness businesses. Net income was $15.8 million, versus $75.6 million a year ago, which had reflected a one-time tax benefit. Adjusted EBITDA increased 53% to $78.4 million.Hims &amp; Hers now has nearly 2.5 million subscribers, up 21% from a year earlier, and monthly revenue per subscriber has also risen 19% to $80. Cash from operations soared to $149 million, while free cash flow for the quarter remained stable at $79 million.Gross margin fell to 74%, from 79% a year earlier, mainly due to changes in shipping cadence and higher production costs related to Hims &amp; Hers’ growing weight-loss portfolio.<h2 class="st-heading-2">Talks With Novo Nordisk</h2>The company said it’s in active talks with Novo Nordisk to make Wegovy injections and an eventual oral formulation available on its platform once they have prescribing approval. No agreement has been reached, and the company said that a deal is not guaranteed.The company said during the earnings call that it expects to bring in over $725 million in weight-loss revenue this year, and that it’s spending money to build new sterile compounding and fulfillment centers to keep up with the surge in demand.<h2 class="st-heading-2">Outlook For 2025</h2>Hims &amp; Hers narrowed its 2025 revenue forecast to a range of $2.335 billion to $2.355 billion, slightly above its previous estimate of $2.3 billion to $2.4 billion. It now expects adjusted EBITDA between $307 million and $317 million, compared with the earlier range of $295 million to $335 million.For the fourth quarter, the company expects revenue of $605 million to $625 million and adjusted EBITDA of $55 million to $65 million. The company said near-term margins will be affected by ongoing investments in its compounding operations and by price adjustments to GLP-1 drugs, though it expects conditions to improve next year as volumes continue to rise.<h2 class="st-heading-2">Stocktwits Traders Bet On Further Gains</h2>On Stocktwits, retail sentiment for Hims was ‘extremely bullish’ amid a 1,734% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/135;" src="https://news.stocktwits-cdn.com/hims_ss_jpg_d349536f51.webp" alt="hims ss.jpg" width="968" height="135"><figcaption>HIMS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed the stock as a solid buy for the next move higher, expecting it to stay above the $30 range.&nbsp;<stembedurl>https://stocktwits.com/Lucy888/message/634788120</stembedurl>Another predicted that shares could climb toward $50 following the company’s strong results and new initiatives. Meanwhile, a third user said the stock could rally sharply once its ongoing discussions with Novo Nordisk are concluded.<stembedurl>https://stocktwits.com/bestest1/message/634776299</stembedurl><stembedurl>https://stocktwits.com/Maximusprofit/message/634778175</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has risen 84% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a HIMS logo is displayed on a smartphone. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.76	--	--	N/A
Q2 '25	$0.92	$0.93	1.42%	BEAT
Q1 '25	$0.91	$0.99	9.16%	BEAT
Q4 '24	$0.83	$0.89	6.80%	BEAT
Q3 '24	$0.88	$0.88	0.19%	BEAT

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest NVO News

NVONovo Nordisk A/S